Based in Cambridge, UK, we are making better medicines by continually improving our antibody discovery technologiesLearn more
Our unique technologies drive the rapid development of effective, human antibody-based drugs across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Two Company sponsored abstracts will be presented One oral presentation and one poster presentation Cambridge, UK; May 16 ...
Kymab submits confidential draft registration statement for proposed initial public offering in the United States
Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced t...
Kymab has received permission to appeal the decision of the UK Court of Appeal to overturn the decision of the High Court trial judge, Mr...
31 May 2019 - 4 Jun 2019 | McCormick Place, Chicago, Illinois, US
View event details